Project Grant R01AI187016
Award Date
8/1/24
Completion Date
6/30/29
Dollars Obligated
$738K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15222, USA
Similar Awards
The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $2.3 million Project Grant to the University of California, Davis to fund research targeting CD4 T follicular helper cells for enhancing HIV vaccine-induced humoral immunity. The two-year award, issued on May 12, 2021 under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support preclinical studies in rhesus macaques to better understand the immunological mechanisms...
This Project Grant award, totaling $859,597, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award aims to develop a vaccine that can elicit broadly neutralizing antibodies (bNAbs) against the HIV-1 fusion peptide epitope, a major vulnerable site on the viral envelope protein. The key product being developed is a recombinant fusion immunogen combining the HIV-1 fusion peptide with...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to design and test novel immunogens for their ability to guide the evolution of the VRC01 B-cell lineage towards a mature phenotype capable of producing broadly neutralizing antibodies against HIV. The total funding amount for this 2-year award is $176,063, with an award date of August 7, 2024 and an...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $242,310.00 to Emory University to study the role of immunoglobulin genetic diversity in the development of neutralizing antibodies against the HIV envelope protein. The project aims to identify genetic polymorphisms and alleles in rhesus macaques associated with differential development of neutralizing...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $7,105,240 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Davis. This 5-year grant, effective December 17, 2024, will support the development of an HIV vaccine regimen that elicits cooperative interactions between env fusion peptide-directed antibodies and follicle-homing helper and cytotoxic T cells. The grant program, titled "OPTIMAL T-CELL...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $3,454,926.00 to Boston Children's Hospital to develop an HIV-1 vaccine strategy focused on the envelope (Env) glycoprotein apex. The key objectives are to: 1) refine the definition of accessible broadly neutralizing antibody (bNAb) precursors against the Env apex that are common in uninfected individuals, and 2)...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to develop an effective HIV vaccine. The key objectives are to: 1) Design and validate a vaccine immunogen focused on the V2B neutralization epitope at the HIV/SIV viral spike apex, and 2) Test the combination of neutralizing anti-V2B antibodies and non-neutralizing, cytotoxic anti-V2C antibodies, along...
This Project Grant award of $910,905 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research by the Scripps Research Institute to develop an HIV vaccine using a lipid nanodisc platform. The key objectives are to: Solve the structures of engineered transmembrane HIV envelope (Env) proteins incorporated into lipid nanodiscs in complex with broadly neutralizing antibodies targeting the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $800,389.00 to Emory University to evaluate the safety and therapeutic potential of a novel strategy towards a cure for HIV infection. The proposed treatment combines soluble IL-15/IL-15RA-FC with a TGF-beta pathway blockade and therapeutic vaccination to enhance and restore function of anti-viral immunity,...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $742,463 in funding to the University of Washington to conduct research on HIV envelope glycoprotein vaccines. The goal is to leverage sequence diversity and glycan holes in naturally occurring HIV envelope proteins to design vaccine immunogens that can induce broadly neutralizing antibodies. The research approach involves in silico modeling,...